FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1900-1907

  Gamliel Lazarovich, Aviva ^a   Gantman, Anna ^a   Coleman, Raymond ^a   Jeng, Arco Y ^b   Kaplan, Marielle ^c   Keidar, Shlomo ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

aldosterone; atherosclerosis; FAD286A; inflammation; macrophages

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; C REACTIVE PROTEIN; FAD 286; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CLINICAL EVALUATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATION; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SODIUM RESTRICTION; TREATMENT OUTCOME;

EID: 85027923977     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c2197     Document Type: Article

References (22)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
3. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19:88-90.
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
5. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003; 41:955-963.
6. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004; 109:2213-2220.
7. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol 2006; 374:153-162.
8. Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, et al., Belgian RALES Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002; 40:1596-1601.
9. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111:3087-3094.
10. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-353.
11. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
12. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol 2001; 335:244-256.
13. el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989; 30:627-630.
14. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1993; 30:111-118.
15. Smythe CD, Skinner VO, Bruckdorfer KR, Haskard DO, Landis RC. The state of macrophage differentiation determines the TNF alpha response to nitrated lipoprotein uptake. Atherosclerosis 2003; 170:213-221.
16. Fuhrman B, Shiner M, Volkova N, Aviram M. Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-to-macrophage differentiation. Free Radic Biol Med 2004; 37:259-271.
17. Ivanovski O, Szumilak D, Nguyen-Khoa T, Dechaux M, Massy ZA, Phan O, et al. Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2005; 180:271-276.
18. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
19. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283:H1802-H1810.
20. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008; 93:817-824.
21. Ménard J, Gonzalez MF, Guyene TT, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24:1147-1155.
22. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75:936-944.